NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Short interest in Mainz Biomed NV (NASDAQ:MYNZ) decreased during the last reporting period, falling from 1.70M to 1.52M. This put 8.25% of the company's publicly available shares short.
From clinical developments to an upcoming FDA trial anticipated in 2025, Mainz Biomed NV MYNZ, the molecular genetics diagnostic company, is making headway in growing its business on its path to ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with ...
and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( NASDAQ:MYNZ ) (“Mainz Biomed” or the“Company”), a molecular genetics diagnostic company specializing in the early ...
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback